Hernandez-Reyes Monserrat, Oo Thura Tun
College of Advanced Studies Cuautitlan, National Autonomous University of Mexico, 54740, Cuautitlan Izcalli, State of Mexico, Mexico.
Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 53792, USA.
Inflammopharmacology. 2025 May 10. doi: 10.1007/s10787-025-01774-2.
Diabetic neuropathy (DNP) is a common complication of diabetes that has a significant impact on the patient's quality of life. The primary objectives of clinical treatment for DNP these days are symptomatic pain management and glycemic control. Since there is currently no cure for nerve damage, the only objective is to alleviate discomfort and slow its progression. Pre-clinical research over the last decade has increasingly linked toll-like receptor 4 (TLR4)-mediated neuroinflammation as a major contributor to DNP development. The role of TLR4-mediated neuroinflammation in the pathophysiology of DNP is covered in this review, along with different therapeutic approaches that target TLR4-mediated neuroinflammation in DNP in pre-clinical research. Despite promising pre-clinical results, translating these findings into clinical practice remains a challenge, which we also discuss how to address and overcome in this review.
糖尿病性神经病变（DNP）是糖尿病常见的并发症，对患者的生活质量有重大影响。目前DNP临床治疗的主要目标是对症疼痛管理和血糖控制。由于目前神经损伤无法治愈，唯一的目标是减轻不适并减缓其进展。过去十年的临床前研究越来越多地将Toll样受体4（TLR4）介导的神经炎症与DNP的发展联系起来。本综述涵盖了TLR4介导的神经炎症在DNP病理生理学中的作用，以及临床前研究中针对DNP中TLR4介导的神经炎症的不同治疗方法。尽管临床前研究结果很有前景，但将这些发现转化为临床实践仍然是一项挑战，我们在本综述中也讨论了如何应对和克服这一挑战。
